Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • Thursday
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive ValueSeeking Alpha • Monday
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 04/11/24
Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille SyndromeBusiness Wire • 04/02/24
Mirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic CholestasisBusiness Wire • 03/13/24
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/28/24
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business UpdateBusiness Wire • 02/28/24
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024Business Wire • 02/21/24
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate UpdatesBusiness Wire • 01/08/24
Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/03/24
Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary AtresiaBusiness Wire • 12/18/23
Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx ConferenceBusiness Wire • 11/20/23